𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Combined androgen blockade for prostate cancer: Review of efficacy, safety and cost-effectiveness

✍ Scribed by Hideyuki Akaza

Book ID
108586924
Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
306 KB
Volume
102
Category
Article
ISSN
1347-9032

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Twenty years of controversy surrounding
Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer
✍ Judd W. Moul πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 71 KB

The current issue of __Cancer__ includes a report on a concise, randomized controlled trial (RCT) with long‐term follow‐up that favors combined androgen blockade with bicalutamide versus lutenizing hormone‐releasing hormone monotherapy in Japanese men with locally advanced and metastatic prostate ca

Development of anemia and recovery in pr
Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy
✍ Asbell, S. O.; Leon, S. A.; Tester, W. J.; Brereton, H. D.; Ago, C. T.; Rotman, πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 488 KB πŸ‘ 2 views

## BACKGROUND. The objective of this study was to document previously unreported anemia in prostate cancer patients treated with neoadjuvant combined androgen blockade (CAB) and pelvic radiotherapy (XRT). METHODS. Four institutions treated 141 patients (mean age f SD, 70.9 ? 6.5 years) with zolad

Systematic review and meta-analysis of m
Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma
✍ David J. Samson; Jerome Seidenfeld; Brian Schmitt; Vic Hasselblad; Peter C. Albe πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 131 KB πŸ‘ 1 views

## Abstract ## BACKGROUND The current systematic review and meta‐analysis compared monotherapy and combined androgen blockade in the treatment of men with advanced prostate carcinoma. Outcomes of interest included overall, cancer specific, and progression‐free survival; time to treatment failure;